Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Co-development deal activity surged 1200% in the six months ending September 2026 — jumping from zero deals in the prior half (September 2025 to March 2026) to 12 deals between March and September 2026. This isn't a gradual uptick. It's a structural shift: Big Pharma is abandoning the traditional acquirer-licensee model for shared-risk, shared-upside co-development partnerships, and the velocity of adoption is unlike anything we've tracked in co-dev deals deal trends 2026.

The Data — Co-Dev Deal Activity, Period over Period

Zero to twelve is not noise. When an entire deal archetype goes from dormant to dominant in a single half-year, it tells you something fundamental has changed in how pharma allocates capital and risk. To put this in context, co-dev structures historically accounted for fewer than 5% of licensing transactions in any given year. Twelve deals in six months suggests co-development is now a preferred mechanism, not an edge case. You can compare this against historical norms using our Deal Benchmarks.

What's Driving the Trend

Pipeline economics have changed. Late-stage clinical programs now regularly cost $500M–$1.2B to bring through Phase III. For assets in oncology combinations, cell therapy, or obesity — where trial complexity is multiplying — no single sponsor wants to carry 100% of the development risk. Co-development structures split costs, typically 50/50 or 60/40, with profit-sharing replacing traditional royalty stacks. The result: both parties de-risk their P&Ls while retaining meaningful upside. This math has become irresistible in a capital environment where pharma CFOs are under pressure to show disciplined deployment.

Competitive dynamics are forcing collaboration. The most valuable therapeutic spaces — GLP-1s, bispecifics, ADCs, next-gen BTK inhibitors — are now so crowded that differentiation depends on combination strategies, geographic reach, or manufacturing scale that no single company owns outright. When Amgen signs co-dev deals with both BeiGene and Novartis in the same week, it signals that even $150B-market-cap companies recognize they can't out-muscle the competition alone. Co-development licensing 2026 is as much about accessing complementary capabilities as it is about sharing costs.

Regulatory tailwinds are accelerating combination development. FDA's evolving guidance on combination therapies — particularly the Project Optimus dose optimization framework and the increasing acceptance of platform trials — has lowered the regulatory friction of co-development. Sponsors can now design trials where two companies share an IND, split CMC responsibilities, and co-market the resulting product with clearer regulatory pathways than existed even two years ago. This removes one of the historical objections to co-dev structures: the operational complexity of shared regulatory accountability.

Notable Deals

Five deals in three days (July 18–20) tells its own story. The Pharmacyclics/AbbVie–Janssen deal is particularly telling: these are companies with a complicated competitive history in hematology, and the fact that they've structured a co-development agreement suggests the asset in question is high-conviction enough — and the development burden expensive enough — to overcome deep institutional rivalry. When former competitors co-develop, the underlying asset economics must be extraordinary.

The AstraZeneca–Merck pairing continues a relationship that has precedent (Lynparza), but its re-emergence in 2026 signals both companies see co-development as the optimal structure for their next wave of assets, not a one-off experiment. Meanwhile, Amgen running parallel co-dev deals with BeiGene and Novartis is a masterclass in strategic optionality — different partners for different geographies or indications, with Amgen retaining leverage by not consolidating all risk with a single counterparty.

The absence of disclosed upfront payments and total deal values across all five deals is itself significant. Co-development structures often minimize or eliminate traditional upfront payments in favor of shared cost obligations and profit splits. This makes headline deal values misleading and traditional Deal Benchmarks less useful unless you're modeling net present value of profit-share scenarios. If you're benchmarking a co-dev term sheet, use Solidus to model the actual economics rather than comparing against upfront-heavy licensing comps.

What This Means for BD Teams Right Now

If you're a biotech with a Phase II+ asset, this is your window. The surge in co-dev deals deal trends 2026 means Big Pharma BD teams are actively seeking partners, not just targets. The distinction matters: in a co-development, you retain equity-like upside instead of selling your asset for milestones. If your data package supports a registrational strategy, you have leverage to negotiate profit-share structures that were inaccessible to biotechs even 18 months ago. Do not default to a traditional license-and-walk-away structure without at least exploring co-development terms.

If you're a pharma BD team, speed is a competitive advantage. Twelve deals in six months means your competitors are already executing. Amgen didn't sign two co-dev deals in one day by accident — they had term sheets ready and governance frameworks pre-negotiated. The teams that win in this environment are the ones with templated co-development agreements, pre-approved JDC (Joint Development Committee) structures, and internal alignment on cost-sharing thresholds before they walk into a partnering meeting.

Deal structures are shifting toward equity-like mechanisms. Traditional structures — upfront plus milestones plus royalties — don't map cleanly onto co-development economics. What we're seeing instead: co-funding commitments with opt-in/opt-out gates at Phase III readouts, 50/50 U.S. profit splits with ex-U.S. royalties, and co-promotion rights that create operational entanglement. These structures require different financial modeling. If your team is still running DCF models built for unilateral licensing deals, you're bringing the wrong toolkit.

Benchmark your deal against current market rates. Whether you're structuring a co-development, licensing, or acquisition, the terms you negotiate should reflect what the market is actually paying — not what it paid two years ago. Use the Ambrosia calculator to stress-test your term sheet against real-time co-dev licensing 2026 comps and ensure you're not leaving value on the table.